CD274 and neoplasm: Sunitinib, a multitargeted receptor tyrosine kinase (RTK) inhibitor approved by the food and drug administration (FDA) at 2006,[10] is currently utilized as a standard of care for both clear cell renal cell carcinoma (ccRCC) and gastrointestinal stromal tumors.[11] However, the role of Sunitinib in tumor immune surveillance and whether it is involved in the regulation of PD‐L1 is completely unknown.